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1. Introduction 
7-Hydroxybutyric a id (GHB) is a minor brain 
catabolite of 7-aminobutyric a id (GABA) which, 
when administered systematically to animals and 
man, induces in both multiple neuropharmacological 
effects (review [ 1 ]). From rat and human brain, two 
enzymes have been isolated which can reduce succinic 
semialdehyde (SSA) to GHB [2-4]. In each case, one 
of these enzymes was non-specific for this reaction 
and could reduce a wide range of aldehydes, whereas 
the other enzyme showed a high degree of specificity 
for SSA reduction. The non-specific SSA reductase 
from both species was strongly inhibited by barbitu- 
rates and various branched-chain fatty acids, whereas 
the specific enzyme was little affected by most of 
these compounds. 
It is of great interest o determine to what extent 
these two enzymes participate in GHB formation in 
vivo. To investigate this, we studied the biosynthesis 
of GHB from labelled GABA in rat brain cerebellar 
slices, an area rich in SSA reductase nzymes [5]. 
These experiments were performed in the absence 
and presence of 3 compounds differentially inhibiting 
the purified enzymes capable of catalyzing the oxida- 
tion of SSA by succinic semialdehyde dehydrogenase 
and its reduction to GHB. 
2. Materials and methods 
SSA was obtained from Sigma and its concentra- 
tion assayed using purified rat brain succinic semi- 
aldehyde dehydrogenase [6]. 2,3-Di-n-propylhexan 
3-ol-oic acid (GT 16) and 4-n-propylheptanoic acid 
(GT 43) were gifts from Dr G. Taillandier (Laboratoire 
de Chimie et de Toxicologie, Universit6 Scientifique 
et M6dicale de Grenoble). [2,3-3H]GABA (spec. act. 
45 Ci/mmol) and [2,3-3H]GHB (spec. act. 40 Ci/ 
retool) were purchased from the CEA (Saclay). 
2.1. Enzyme assays used to test the effects o f  the 
three potential inhibitors 
(1) GABA-transaminase (GABA-T, EC 2.6.1.19): 
This activity was determined by the radiometric 
method in [7] using a 30 000 × g supernatant solu- 
tion of rat brain, but with GABA at 2 mM, which is 
similar to the level of GABA found in brain tissue, 
and a-ketoglutarate at 0.7 mM Krebs-Ringer bicar- 
bonate buffer (pH 7.4) was used. 
(2) Succinic semialdehyde hydrogenase (SSADH, 
EC 1.2.1.16): Pure SSADH prepared as in [6] was 
used. The assay conditions were identical to those in 
[6] except hat SSA was 10 -s M and that the same 
buffer as in (1) was used. 
(3) Succinic semialdehyde r ductases (SSR, EC 
1.1.1.2): Pure non-specific and specific SSA reduc- 
tases from rat brain prepared as in [3] were employed 
and the assay methods were identical to those in [3]. 
For the 4 enzymes, inhibitors were tested at 
10 -3 M. Enzyme assays were performed in triplicate. 
2.2. Preparation o f  tissue slices 
Male Wistar rats (~150 g body wt) were used. The 
animals were decapitated after stunning and the cere- 
bella were rapidly removed and sliced with a mechan- 
ical chopper perpendicularly to the pial surface to 
give ~0.5 mm sections. Each slice was then chopped 
into 1 mm sections in both planes. 
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2.3. Incubation method 
For each incubation, ~100 mg of this tissue were 
weighed and placed in tubes containing 1ml cold 
Krebs-Ringer bicarbonate buffer (NaC1 122 mM, KC1 
3.1 mM, CaC12 1.3 mM, MgSO4 1.2 mM, KH2PO4 
0.4 mM, NaHCOa 24.4 mM, glucose 10 mM) pre- 
gassed with 95% 02: 5% CO2. The tubes were then 
sealed after replacing the air with 95% O2: 5% CO2. 
Preincubations were carried out at 37°C for 10 rain in 
the absence and presence of the enzyme inhibitors. 
Then 25 juCi [2,3-aH]GABA were injected into all the 
tubes which were incubated at 37°C for a further 
30 rain with gentle agitation. Incorporation of GABA 
into GHB is linear during this period. The incubation 
was terminated by injection of 120/al 10 M HC1. 
GHB (2.5/amol) in 50/al were added prior to homog- 
enisation for 30 s using a Polytron homogeniser at
setting 6. The homogenates were then centrifuged for 
20 min at 20 000 × g. The resulting pellets were 
re-extracted with 1 ml of 1 M HC1. The pooled super- 
natants were heated at 85°C for 30 min to lactonise 
GHB. After cooling, the 3,-butyrolactone was extracted 
twice with 2 ml chloroform and the pooled extracts 
were concentrated at room temperature under a gen- 
tle stream of N2 to ~100/A. 
2.4. Purification and measurement of  radioactive 
GHB 
All of each concentrated xtract was subjected to 
thin-layer chromatography on 20 X 20 cm silica gel 
plates (Merck) and the chromatograms were developed 
in benzene/ether (70:30) until the solvent front had 
reached 12 cm from the origin. After drying, each 
plate was scanned with a Berthold linear/3-counter to 
determined the position of 3'-[aH]butyrolactone- A 
control run was made using pure 7-[3H]butyro - 
lactone. The spots corresponding to 7-[aH]butyro - 
lactone were scraped off the plates and extracted 
twice with 1 ml ethyl acetate, the pooled extracts 
were evaporated to ~1 ml under a stream of N2, and 
100/ag 5-valerolactone w re added. The yield of 
3,-butyrolactone from the extraction procedure was 
determined by gas chromatography using a flame 
ionisation detector (Perkin Elmer Sigma 3) as in [8]. 
A linear calibration plot for the GBL standard in 
ethyl acetate was obtained by plotting the peak area 
ratio vs the amount of GBL By linear regression, a
straight line was obtained (r = 0.999) between 
5-100 #g GBL with 100 ~g 8-valerolactone. The 
remainder of the ethyl acetate xtracts (99.9% of the 
Table 1 
Percent inhibition 
Inhibitor a GABA-T SSADH Specific Non-specific 
SSR SSR 
GT 16 12 86 n.d. 84 
GT 43 12 80 40 74 
Barbital n.d. 13 n.d. 80 
a Final concentration, 10 -3 M; 
n.d., No inhibition detected under our assay condition 
Values are the mean of triplicate determinations which varied 
<10% 
total) was subjected to liquid scintillation counting. 
Disintegrations per minute were obtained using a 
quenching curve. Statistical analysis of data were car- 
ried out using Student's t-test. 
3. Results 
The percentage inhibition values for the 3 com- 
pounds tested by the assay method escribed for the 
4 enzymes, are given in table 1. All 3 compounds 
strongly inhibit non-specific SSA reductase but in 
addition GT 16 and GT 43 are also strong inhibitors 
of SSADH. Only GT 43 is a significant inhibitor of 
the specific SSA reductase. GABA-T activity is ve(y 
slightly inhibited by the 2 branched-chain fatty acids 
and barbital has no effect on this enzyme. Table 2 
shows the levels of incorporation of [3H] GABA into 
GHB after 30 min incubation in the absence and 
presence of the 3 enzyme inhibitors. Catabolism of 
[3HI GHB under our incubation conditions was negli- 
Table 2 
Conversion of [3H]GABA to [3H]GHB in rat brain cerebeUar 
slices 
Experimental GHB formed (10 -12 mol .  Change 
procedure min -1 . g tissue -1, w/w) (%) 
Control 612 ± 46 (12) - 
GT 16 (10 -3 M) 872-+ 78 (4) a +42.5 
GT 16 (2 × 10 -3 M) 1062 -+ 104 (3) a +73.6 
GT 43 (10 -s M) 550 ± 4 (3) a -10.0 
Barbital (10 -3 M) 654 ± 27 (3) b +6.8 
a Significantly different from control (p < 0.001) 
b Significantly different from control (p < 0.01) 
Results are expressed as the mean ± SD (no expt) 
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gible over 30 min. The levels of GABA incorporation 
into GHB were calculated assuming a cerebellar level 
of 1.3 gmol/g wet tissue wt as determined in [9]. 
Barbital induces a slight increase in [all] GABA 
incorporation i to GHB, GT 16 induces a large 
increase in incorporation, that is almost concentra- 
tion-dependent, whereas GT 43 causes a significant 
drop in incorporation. 
4. Discussion 
Under our experimental conditions, [3H] GABA is 
incorporated into GHB, but for reasons not yet 
understood, the further catabolism of GHB does not 
take place to a significant extent. However, in vivo, 
GHB must be catabolised at about the same rate as it 
is synthesized, and there are several arguments which 
indicate that this catabolism does not occur by a 
direct reversal of GHB synthesis [5]. It might be sug- 
gested that some metabolic intermediate or cofactor 
required for the catabolism of GHB is not produced 
by cerebellar brain slices which are respiring in Krebs- 
Ringer bicarbonate glucose medium, although the 
GABA shunt pathway appears to be functioning nor- 
mally. The pool of cerebellar GABA has been calcu- 
lated to be 1.3/~mol/g fresh wt [9] and under our 
conditions, ~0.05% of this pool is converted to 
GHB/min. This value is somewhat lower than that 
found in vivo in [10] where 0.16% of whole brain 
GABA was incorporated into GHB/min after intra- 
ventricular injection of a pulse of labelled GABA. 
Nevertheless, the effect of certain drugs observed on 
this system is compatible with their selective action 
on the enzymes involved in GHB synthesis. 
The 3 compounds inhibit only slightly or not at all 
GABA-T whereas they all strongly inhibit non spe- 
cific SSA reductase. If this latter enzyme which is 
present in large excess over the specific enzyme in rat 
brain tissue [5 ] was involved in SSA reduction, a large 
decrease in GHB formation would be expected in GHB 
formation in the presence of each compound. Evidently 
this is not the case. The 2 branched-chain fatty acids 
are inhibitors of SSADH and they would thus be 
expected to increase the pool of SSA available for 
reduction to GHB. Indeed, GT 16 does increase the 
incorporation of GABA into GHB in a dose-dependent 
manner whereas GT 43 actually elicits a slight decrease. 
This phenomenon may be explained by the fact that 
only the latter compound is an inhibitor of specific 
SSA reductase. Barbital, which is a strong inhibitor 
only of the non-specific SSA reductase has little effect 
on the incorporation i to GHB. These results strongly 
suggest that the specific SSA reductase is uniquely 
involved in SSA reduction to GHB in brain slices, and 
hence most probably in vivo. 
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